A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23

Saito, Y., Yin, D., Kubota, N., Wang, X., Filliol, A., Remotti, H., Nair, A., Fazlollahi, L., Hoshida, Y., Tabas, I., Wangensteen, K. J., & Schwabe, R. F. (2023). A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23. Gastroenterology, 164(7), 1279–1292. https://doi.org/10.1053/j.gastro.2023.02.043
Authors:
Yoshinobu Saito
Dingzi Yin
Naoto Kubota
Xiaobo Wang
Aveline Filliol
Helen Remotti
Ajay Nair
Ladan Fazlollahi
Yujin Hoshida
Ira Tabas
Kirk J. Wangensteen
Robert F. Schwabe
Affiliated Authors:
Yoshinobu Saito
Xiaobo Wang
Aveline Filliol
Helen Remotti
Ajay Nair
Ladan Fazlollahi
Ira Tabas
Robert F. Schwabe
Columbia Affiliation:
Subjects:
Carcinoma, Hepatocellular (MeSH)
Liver Neoplasms (MeSH)
Role of Hippo Signaling Pathway in Mechanotransduction (OpenAlex Topic)
Protein Arginine Methylation in Mammals (OpenAlex Topic)
Ubiquitin-Proteasome Proteolytic Pathway (OpenAlex Topic)
Author Keywords:
anillin
combination therapy
crispr
immune checkpoint inhibition
kinesin family member 23
liver cancer
statin
tyrosine kinase inhibitor
vt104
vt107
elink
Publication Type:
Article
Unique ID:
10.1053/j.gastro.2023.02.043
PMID:
36894036
DOI:
10.1053/j.gastro.2023.02.043
Journal:
Gastroenterology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record

Record Created: